Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BRISOTE: A Multicentre, Randomised, Double-Blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting β2-Agonist.

NCT06750289 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06750289
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06750289 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BRISOTE: A Multicentre, Randomised, Double-Blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting β2-Agonist.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
March 28, 2025
Completion date
November 3, 2028
Enrollment
400 (estimated)
Sites
160

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic asthma